ArticlePeerJ2026
Frequent exposure to biologics is associated with small intestinal bacterial overgrowth in patients with Crohn's disease: a retrospective case-control study.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small intestinal bacterial overgrowth (SIBO) is characterized by excessive bacteria in the small intestine, often accompanied by gastrointestinal symptoms. The advent of biologic therapies has significantly advanced the treatment of Crohn's disease (CD), yet their influence on the development of SIBO remains unclear. Aims: This study aims to elucidate the relationship between exposure to biologic therapies and the incidence of SIBO in CD patients. Methods: This retrospective case-control study enrolled CD patients who underwent lactulose hydrogen-methane breath test (LHMBT) at Jinling Hospital from 2021 to 2024. Clinical data were collected and the risk factors for SIBO were identified using both univariate and multivariate logistic regression. Additionally, model validation was carried out using receiver operating characteristic (ROC) curve analysis, confusion matrix and 5-fold cross-validation. Results: (1) Among the 86 CD patients enrolled, biologic administration differed significantly between the SIBO-positive ( Conclusions: This study indicated that frequent exposure to biologics is associated with an increased presence of SIBO in CD patients, particularly in those with intestinal strictures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.